We report about a MEDLINE research from 2000 to 2005 with the key words 'positron emission tomography ANDyOR mediastinoscopy'. The search identified 448 potential studies. Out of the published data sensitivity, specificity, positive and negative predictive value, and accuracy for mediastinal lymph node staging by FDG-PET ranged from 58%-94%, 76%-96%, 43%-95%, 56%-98% to 74%-91%, respectively. With corresponding values of 80%-96%, 100%, 100%, 92%-97%, and 94%, respectively, for mediastinoscopy. FDG-PET improved the rate of detection of local and distant metastases in 12% to 62% and changed the management of treatment in 8% to 60% of patients with NSCLC. Our study shows that in the diagnostic strategy of patients with NSCLC, additional FDG-PET can prevent non-therapeutic thoracotomy in a significant number of cases. If FDG-PET imaging and CT scan is negative for mediastinal lymph node involvement routinely mediastinoscopy can be omitted and thoracotomy can immediately be performed. In patients with negative FDG-PET scan, but positive CT scan, histologic verification by invasive methods can individually be considered. Patients with positive FDG-PET scan mediastinoscopy still remain a reliable standard for exact lymph node staging. By incorporating FDG-PET in clinical staging unnecessary exploratory thoracotomies, and mediastinoscopy, can be omitted.
Introduction
Pathologic staging in patients with newly diagnosed nonsmall cell lung cancer (NSCLC) is of substantial importance determining the best possible therapeutic option, clarifying operability, detecting prognosis, and is essential in clinical trials comparing different management strategies, and enables universal communication regarding the efficacy of different treatments in specific patient groups. The likelihood of the surgical cure of primary NSCLC is strongly dependent on the local extent of the cancer, particularly whether or not the mediastinal lymph nodes are involved with cancer or whether extrathoracic metastases are present w1x. Mediastinal lymph node involvement is reported to be present in 28% to 38% of NSCLC at the time of diagnosis, and if present has an important bearing on the treatment plan w2x. Complete pathologic staging as derived from complete mediastinal lymph node dissection is the accurate way of providing definitive staging information. Additional FDG-PET diagnostics leads to avoid ineffective therapies, particularly unnecessary thoracotomy.
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scopy in lymph node staging in patients with NSCLC as well as to question to what extent FDG-PET may bypass mediastinoscopy in some cases.
Methods
We performed a MEDLINE analysis restricted to the years 2000 to 2005 with the key words 'positron emission tomography ANDyOR mediastinoscopy' (448 hits). The diagnostic value of FDG-PET, CT, and mediastinoscopy were defined by sensitivity, specificity, positive and negative predictive value, and accuracy, respectively.
Results
The MEDLINE search identified 448 potential studies. We selected 28 articles (3 meta-analyses, 17 prospective and 8 retrospective articles). All other studies were excluded after scanning their abstracts, including studies written in another language other than English or German, or because of insufficient data reported, respectively.
2-w FxFluoro-2-deoxy-D-glucose positron emission 18 tomography (FDG-PET)
Positron emission tomography, a non-invasive imaging modality with the metabolic tracer F-18-fluorodeoxyglucose allows for functional characterization of tissues. The Downloaded from https://academic.oup.com/icvts/article-abstract/5/4/418/672655 by guest on 04 February 2019 
Cervical and anterior mediastinoscopy
In the work-up for a thoracotomy in patients with NSCLC mediastionoscopy is considered to be an accurate method, providing a high negative and positive predictive value, and a low morbidity and mortality rate. The only anatomic contraindication is the presence of a permanent tracheostomy. Anterior mediastinoscopy is performed when the primary lesion originates in the left upper lobe or left hilium, or when there is suspicious adenopathy in the anterior mediastinum or aortopulmonary window w4x. But mediastinosocopy can lead to false-negative results, because not all lymph node stations could easily be reached (i.e. subcarinal area, paraesophageal area, and pulmonary ligament). Furthermore, mediastinoscopy is associated with a low but present risk of serious complications (in 0.5% of the patients), including hemorrhage, mediastinitis, pneumothorax, or vocal cord paralysis ( Table 2 ).
Discussion
Many authors propose that only patients with positive FDG-PET scan do require mediastinoscopy before exploration for resection and mediastinal lymph node dissection, others recommend performing mediastinoscopy on every patient with potentially operable NSCLC w5,6x. This advice is justified because of the fact that the use of FDG-PET can lead to false-positive and false-negative results. A positive Downloaded from https://academic.oup.com/icvts/article-abstract/5/4/418/672655 by guest on 04 February 2019 FDG-PET scan result does not necessarily represent malignant disease, and histological confirmation is always warranted.
FDG-PET versus CT-scan
CT-scan is neither sufficiently sensitive nor specific in identifying lymph node metastases. FDG-PET provides information regarding the functional activity of a malignant lesion rather than strictly anatomic information as is provided by computed tomography (CT) w7x. Several studies have shown that FDG-PET is superior to CT scan in staging mediastinal lymph node involvement in patients with NSCLC (Table 3) . Cerfolio et al. w8x prospectively assessed the role of FDG-PET and CT scan in staging 400 patients with NSCLC. Suspicious N2 lymph nodes by either chest CT or by FDG-PET scan were biopsied. In this study, it could be demonstrated that FDG-PET had a higher sensitivity (71% vs. 43%, P-0.001), positive predictive value (44% vs. 31%, P-0.001), negative predictive value (91% vs. 84%, Ps0.006), and accuracy (76% vs. 68%, Ps0.037) than CT scan for N2 lymph nodes. Similarly, FDG-PET had a higher sensitivity (67% vs. 41%, P-0.001), but lower specificity (78% vs. 88%, Ps0.009) than CT scan for N1 lymph nodes. Furthermore, the authors could show that FDG-PET was most commonly falsely negative in the subcarinal station and the aortopulmonary window lymph node stations w8x. Hellwig et al. investigated 20 studies for FDG-PET imaging (ns1292 patients) and found a sensitivity of 88%, specificity of 92%, and accuracy of 91%, respectively, versus 19 studies for CT-scan (ns1268 patients) with a sensitivity of 65%, specificity of 76%, and accuracy of 73%, respectively w9x. Birim et al. found 17 studies with 833 patients. Sensitivity and specificity were determined using the area under the receiver operating characteristic (ROC) curve.
The point on the ROC with equal sensitivity and specificity for FDG-PET was 0.9. For CT it was 0.7. The difference was highly significant (P-0.0001) w1x.
Several trials could prove a significant improvement of integrated PET-CT compared to FDG-PET alone (Table 4) .
Mediastinoscopy
Mediastinoscopy, first described by Carlens and associates in 1959, is an invasive procedure with a low but present risk of serious complications. In many clinics mediastinoscopy is not a standard procedure for mediastinal lymph node staging. The utility of mediastinoscopy in the presence of normal-sized mediastinal lymph nodes is more controversial. Even patients with peripheral T1 tumors and no mediastinal adenopathy according to CT may be found to have positive mediastinal lymph nodes in up to 20% of cases. Because N2 disease is a strong marker for probable occult distant metastatic disease, many thoracic surgeons routinely perform mediastinoscopy, which provides the opportunity to consider induction therapy before thoracotomy w10x. Therefore, lymph node sampling or lymph node dissection by means of invasive procedures (cervical andy or anterior mediastinoscopy) provides the definitive possibility for pathologic staging. Daniels et al. investigated 76 patients with NSCLC and performed mediastinoscopy on every patient with potentially operable NSCLC (except for T1 squamous cell carcinoma). Ten percent of the patients were prevented from exploratory thoracotomy by the routine use of mediastinoscopy. The authors conclude that mediastinoscopy should be performed on every patient with possibly operable NSCLC, regardless of the outcome of CT, except for patients with T1 squamous cell carcinoma w6x. Because it is neither practical nor economical to recommend mediastinoscopy for all candidates for surgery, Kimura et al. have developed -in a prospective study with 121 patients -indication criteria for cervical mediastinoscopy.
Patients with resectable NSCLC were chosen for mediastinoscopy when at least one of three clinical indicators was present: (1) computed tomographic evidence of mediastinal adenopathy, (2) elevated levels of serologic tumor markers, and (3) diameters of primary cancers 2 to 3 cm. Pathologic examinations after mediastinoscopy indicate that the diagnostic sensitivity and negative predictive value for the postulated indication criteria were 95.8% and 97.4%, respectively. Using three indicators for N2 prediction the authors avoided 37% unnecessary mediastinoscopies. FDG-PET was less effective than the three criteria, yielding 70% (diagnostic sensitivity), 86% (specificity), and 84% (accuracy), respectively w11x.
Comparison of FDG-PET to mediastinoscopy
Several reports tried to answer the question whether FDG-PET can reduce the need for mediastionoscopy in patients who are potentially eligible for a curative resection and to what extent FDG-PET is able to affect management of treatment. Actually, only prospective studies that compare FDG-PET scanning to detect lymph node metastases versus other methods do provide a truly definitive answer. In the year 2001, Poncelet et al. tried to assess -in a prospective study with 64 patients -the effectiveness of FDG-PET in mediastinal lymph node staging for NSCLC and compared it to conventional clinical and surgical staging. This study showed that FDG-PET imaging strength lies in its very high negative predictive value and increased sensitivity. Combinded with chest CT-scan preoperatively, it may alleviate the need for surgical staging when FDG-PET studies of the mediastinum are negative. However, with a positive FDG-PET scan result, further diagnostic procedures should be pursued in order to avoid overstaging and allow better surgical patient selection w12x. On the other hand, Gonzalez-Stawinski et al. compared prospectively the efficacy of FDG-PET to mediastinoscopy in 202 patients with known NSCLC. Of the 65y202 patients (32.2%) with positive results of FDG-PET, only 29 patients had positive results of mediastinoscopy in the corresponding nodal station. Of the 137 patients with negative results of FDG-PET, 16 patients (11.7%) were demonstrated to have N2 or N3 disease. Therefore, the authors concluded that FDG-PET neither confirms nor excludes involvement of the mediastinum in patients with NSCLC and cervical mediastinoscopy with lymph node biopsy remains the criterion standard for mediastinal staging. In this study the false-positive results (55.4%) of mediastinal FDG-PET included granulomatous inflammation, sinus histiocytosis, and silicosis w5x. Also Kernstine w13x could demonstrate results with 237 patients (sensitivity of FDG-PET of 68%, specificity of 82%, positive predictive value of 54%, and negative predictive value of 89%). On the basis of these results, the author concluded, that relative to mediastinoscopy FDG-PET alone is not sufficient to accurately stage the mediastinum and that mediastinoscopy should continue to be performed in potentially operable cases. The author summarized the impact of FDG-PET in the clinical management: (1) it is useful in diagnosis and staging, though it neither diagnoses nor excludes the presence of malignancy; (2) it can discriminate less suitable candidates for surgical resection, estimated to be 20% to 25% of potential surgical patients; and (3) it may provide helpful prognostic information in additional to the staging information. Even Verhagen et al. assessed prospectively the impact of adding FDG-PET to full conventional clinical staging. The authors concluded that by incorporating FDG-PET in clinical staging, 15% of patients with NSCLC are upstaged due to unexpected extrathoracic metastases. In case of a negative mediastinal FDG-PET scan, mediastinoscopy can only be omitted in the presence of a non-centrally located primary tumor and without FDG-PET positive N1 nodes w10x. The PLUS (PET in LUng cancer Staging; multicenter trial with 188 patients) study was designed to work with routine clinical workup of patients with suspected NSCLC. The authors compared the current strategy of conventional diagnostic methods with a strategy in which FDG-PET was added to non-invasive diagnostic techniques. The results showed that addition of FDG-PET to conventional workup prevented unnecessary surgery in one out of five patients with suspected NSCLC w15x. Also, the American College of Surgeons Oncology Group undertook a trial to ascertain whether FDG-PET could detect lesions that would preclude pulmonary resection in a group of patients with documented or suspected NSCLC. They found that in patients with suspected or proven NSCLC considered respectable by standard staging procedures, FDG-PET can prevent non-therapeutic thoracotomy in a significant number of cases. By correctly identifying advanced disease (stages IIIA, IIIB, and IV) or benign lesions, FDG-PET potentially avoided unnecessary thoracotomy in 1 the T and N status of patients with NSCLC when compared with dedicated PET alone. It is more accurate at some nodal stations but still only achieves an accuracy of 96% and 90% for the N2 and N1 nodes, respectively. Verhagen et al., 2004, w10x By incorporating FDG-PET in clinical staging, 15% of patients with lung cancer are upstaged due to unexpected extrathoracic metastases. In case of a negative mediastinal FDG-PET, mediastinoscopy can only be omitted in the presence of a non-centrally located primary tumor and without FDG-PET positive N1 nodes. Reed et al., 2003, w7x In patients with suspected or proven NSCLC considered resectable by standard staging procedures, FDG-PET can prevent nontherapeutic thoracotomy in a significant number of cases. Use of FDG-PET for mediastinal staging should not be relied on as a sole staging modality, and positive findings should be confirmed by mediastinoscopy. Metastatic disease, especially a single site, identified by FDG-PET requires further confirmatory evaluation. Lardinois et al., 2003, wN Engl J Med; 348:2500 Integrated PET-CT improves the diagnostic accuracy of the staging of NSCLC. van Tinteren et al., 2002, w15x Addition of FDG-PET to conventional workup prevented unnecessary surgery in one out of five patients with suspected NSCLC. Kernstine et al., 2002, w4x In NSCLC PET may reduce the necessity for mediastinoscopy when the primary lesion standardized uptake value is less than 2.5 and the mediastinum is PET negative. Accepting this approach in our patient population, the need for mediastinoscopy would have been reduced by 12%. Gupta et al., 2001, wChest; 120:521-527x The false-positive findings of FDG-PET imaging affected selection of treatment in 83% of patients. FDG-PET imaging strength lies in its very high negative predictive value and increased sensitivity. The overall accuracy of FDG-PET scan (82%) was lower than previously reported. Combined with chest CT-scan preoperatively, it may alleviate the need for surgical staging when FDG-PET studies of the mediastinum are negative. However, with a positive FDG-PET scan result, further diagnostic procedures should be pursued in order to avoid overstaging and allow better surgical patient selection. Hellwig et al., 2001, w9x Studies with in total more than 1000 patients show the high diagnostic efficacy of FDG-PET and its superiority to conventional imaging in lung cancer. Based on this analysis FDG-PET is evaluated as a 1a indication of lung nodules in patients at risk for complications during surgery, N-staging, M-staging (except brain), and detection of recurrence. Pieterman et al., 2000, wN Engl J FDG-PET improves the rate of detection of local and distant metastases in patients Med; with NSCLC. The use of FDG-PET for clinical staging resulted in a different stage from the one determined by standard methods in 62y102 patients (lowered in 20 and raised in 42 patients).
of 5 patients w7x. Furthermore, several studies pointed out that by adding FDG-PET to conventional staging the management of treatment is changed in 8% to 60% of patients and prevents unnecessary invasive exploratory thoracotomy, and mediastinoscopy in 12% to 62% (Table 5) .
Conclusions
In conclusion, the results of these studies indicate that in patients with NSCLC incorporating FDG-PET in clinical staging can prevent unnecessary invasive procedures in a significant number of cases. If FDG-PET imaging and CT scan is negative for mediastinal lymph node involvement routinely mediastinoscopy can be omitted and thoracotomy can immediately be performed. In patients with negative FDG-PET scan, but positive CT scan, histological verification by invasive methods can individually be considered. In patients with positive FDG-PET scan mediastinoscopy still remains the definitive method for exact lymph node staging.
